Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 208.85
(3.37%)
INR 208.85
(3.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 508.13 Million INR | -37.43% |
| 2022 | 342.07 Million INR | 38.96% |
| 2021 | 246.17 Million INR | 36.64% |
| 2020 | 180.16 Million INR | 140.74% |
| 2019 | 74.83 Million INR | -10.11% |
| 2018 | 83.25 Million INR | 172.97% |
| 2017 | -114.09 Million INR | -179.25% |
| 2016 | 143.96 Million INR | 253.28% |
| 2015 | 40.75 Million INR | 143.78% |
| 2014 | 16.71 Million INR | -33.92% |
| 2013 | 25.29 Million INR | 12.68% |
| 2012 | 22.45 Million INR | -77.02% |
| 2011 | 97.68 Million INR | 5.4% |
| 2010 | 92.68 Million INR | -11.73% |
| 2009 | 105 Million INR | 6.08% |
| 2008 | 98.98 Million INR | 90.65% |
| 2007 | 51.91 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 91.66 Million INR | 304.5% |
| 2024 Q2 | 139.44 Million INR | 52.13% |
| 2023 Q1 | 82.44 Million INR | 66.26% |
| 2023 Q2 | 79.1 Million INR | -4.05% |
| 2023 Q3 | 29.84 Million INR | -62.28% |
| 2023 FY | 214.04 Million INR | -37.43% |
| 2023 Q4 | 22.66 Million INR | -24.06% |
| 2022 Q3 | 83.03 Million INR | -34.61% |
| 2022 Q1 | 62.24 Million INR | 36082.08% |
| 2022 FY | 342.07 Million INR | 38.96% |
| 2022 Q4 | 49.58 Million INR | -40.29% |
| 2022 Q2 | 126.98 Million INR | 104.0% |
| 2021 Q4 | -173 Thousand INR | -100.33% |
| 2021 FY | 246.17 Million INR | 36.64% |
| 2021 Q3 | 52.41 Million INR | -47.87% |
| 2021 Q2 | 100.53 Million INR | 11.81% |
| 2021 Q1 | 89.91 Million INR | 85.28% |
| 2020 FY | 180.16 Million INR | 140.74% |
| 2020 Q3 | 67.43 Million INR | 35.32% |
| 2020 Q2 | 49.83 Million INR | 57.88% |
| 2020 Q1 | 31.56 Million INR | 103.38% |
| 2020 Q4 | 48.52 Million INR | -28.04% |
| 2019 Q4 | 15.51 Million INR | -47.49% |
| 2019 FY | 74.83 Million INR | -10.11% |
| 2019 Q1 | 26.22 Million INR | -29.3% |
| 2019 Q3 | 29.55 Million INR | 10.09% |
| 2019 Q2 | 26.84 Million INR | 2.37% |
| 2018 Q1 | 10.79 Million INR | 196.77% |
| 2018 Q2 | 24.09 Million INR | 123.15% |
| 2018 Q3 | 22.48 Million INR | -6.69% |
| 2018 Q4 | 37.08 Million INR | 64.95% |
| 2018 FY | 83.25 Million INR | 172.97% |
| 2017 Q1 | 42.2 Million INR | 4233.37% |
| 2017 Q4 | -11.15 Million INR | 51.33% |
| 2017 Q3 | -22.92 Million INR | 41.88% |
| 2017 Q2 | -39.44 Million INR | -193.46% |
| 2017 FY | -114.09 Million INR | -179.25% |
| 2016 Q1 | 8.01 Million INR | -66.01% |
| 2016 FY | 143.96 Million INR | 253.28% |
| 2016 Q2 | 6.29 Million INR | -21.5% |
| 2016 Q3 | 128.68 Million INR | 1944.86% |
| 2016 Q4 | 974 Thousand INR | -99.24% |
| 2015 FY | 40.75 Million INR | 143.78% |
| 2015 Q4 | 23.58 Million INR | 384.95% |
| 2015 Q3 | 4.86 Million INR | -18.59% |
| 2015 Q2 | 5.97 Million INR | -5.53% |
| 2015 Q1 | 6.32 Million INR | 1028.78% |
| 2014 Q3 | 328 Thousand INR | -95.29% |
| 2014 Q2 | 6.97 Million INR | -30.97% |
| 2014 Q1 | 10.09 Million INR | -19.4% |
| 2014 FY | 16.71 Million INR | -33.92% |
| 2014 Q4 | -681 Thousand INR | -307.62% |
| 2013 Q1 | 86 Thousand INR | 104.12% |
| 2013 Q2 | 959 Thousand INR | 1015.12% |
| 2013 Q4 | 12.52 Million INR | 6.71% |
| 2013 Q3 | 11.74 Million INR | 1124.19% |
| 2013 FY | 25.29 Million INR | 12.68% |
| 2012 Q1 | 1.5 Million INR | -88.14% |
| 2012 Q2 | 7.49 Million INR | 397.61% |
| 2012 Q3 | 15.54 Million INR | 107.37% |
| 2012 Q4 | -2.08 Million INR | -113.44% |
| 2012 FY | 22.45 Million INR | -77.02% |
| 2011 FY | 97.68 Million INR | 5.4% |
| 2011 Q3 | 31.74 Million INR | -2.92% |
| 2011 Q2 | 32.7 Million INR | 0.0% |
| 2011 Q4 | 12.69 Million INR | -60.0% |
| 2010 FY | 92.68 Million INR | -11.73% |
| 2009 FY | 105 Million INR | 6.08% |
| 2008 FY | 98.98 Million INR | 90.65% |
| 2007 FY | 51.91 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 91.175% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 98.796% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 94.341% |
| Granules India Limited | 6.81 Billion INR | 92.546% |
| Indoco Remedies Limited | 1.29 Billion INR | 60.688% |
| Achyut Healthcare Limited | 4.43 Million INR | -11349.527% |
| Ajanta Pharma Limited | 19.67 Billion INR | 97.418% |
| Alkem Laboratories Limited | 19.46 Billion INR | 97.389% |
| Alpa Laboratories Limited | 184.49 Million INR | -175.414% |
| Brooks Laboratories Limited | 14.44 Million INR | -3418.906% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 70.415% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 58.722% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.25% |
| Eris Lifesciences Limited | 5.18 Billion INR | 90.194% |
| FDC Limited | 2.98 Billion INR | 82.984% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 92.185% |
| Gufic Biosciences Limited | 1.32 Billion INR | 61.792% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 88.505% |
| Ipca Laboratories Limited | 7.98 Billion INR | 93.633% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 434.391% |
| Lasa Supergenerics Limited | -458 Million INR | 210.944% |
| Laurus Labs Limited | 3.94 Billion INR | 87.131% |
| Lupin Limited | 28.04 Billion INR | 98.188% |
| Mankind Pharma Limited | 21.51 Billion INR | 97.639% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -406.61% |
| Megasoft Limited | -121.1 Million INR | 519.582% |
| NATCO Pharma Limited | 25.96 Billion INR | 98.043% |
| Piramal Pharma Limited | 4.55 Billion INR | 88.849% |
| RPG Life Sciences Limited | 2.29 Billion INR | 77.833% |
| Sigachi Industries Limited | 1.47 Billion INR | 65.525% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.513% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 88.972% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -103.863% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 10.81% |
| Windlas Biotech Limited | 1.29 Billion INR | 60.88% |
| ZIM Laboratories Limited | 253.82 Million INR | -100.186% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 98.821% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 112.348% |
| Divi's Laboratories Limited | 33.08 Billion INR | 98.464% |
| Hester Biosciences Limited | 364.81 Million INR | -39.286% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 81.761% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -11.056% |
| Bal Pharma Limited | 233.9 Million INR | -117.234% |
| Strides Pharma Science Limited | 5.22 Billion INR | 90.277% |
| Venus Remedies Limited | 534.65 Million INR | 4.96% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 83.756% |
| Nectar Lifesciences Limited | 923.8 Million INR | 44.996% |
| Shilpa Medicare Limited | 1.36 Billion INR | 62.809% |
| Aarti Drugs Limited | 7.14 Billion INR | 92.892% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 68.178% |
| Suven Life Sciences Limited | -1.22 Billion INR | 141.452% |
| Ind-Swift Limited | 1.22 Billion INR | 58.553% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 96.442% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 113.188% |
| Themis Medicare Limited | 392.58 Million INR | -29.431% |
| Hikal Limited | 32.11 Million INR | -1482.467% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 97.994% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 18.894% |
| Wockhardt Limited | -670 Million INR | 175.84% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 90.208% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -5503.118% |
| Neuland Laboratories Limited | 5.31 Billion INR | 90.445% |
| Morepen Laboratories Limited | 4.17 Billion INR | 87.826% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -144.235% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -1750.572% |